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Abstract
The essential transactivator function of the HIV Tat protein is regulated by multiple posttranslational modifications.
Although individual modifications are well characterized, their crosstalk and dynamics of occurrence during the HIV
transcription cycle remain unclear. We examine interactions between two critical modifications within the RNA-binding
domain of Tat: monomethylation of lysine 51 (K51) mediated by Set7/9/KMT7, an early event in the Tat transactivation cycle
that strengthens the interaction of Tat with TAR RNA, and acetylation of lysine 50 (K50) mediated by p300/KAT3B, a later
process that dissociates the complex formed by Tat, TAR RNA and the cyclin T1 subunit of the positive transcription
elongation factor b (P-TEFb). We find K51 monomethylation inhibited in synthetic Tat peptides carrying an acetyl group at
K50 while acetylation can occur in methylated peptides, albeit at a reduced rate. To examine whether Tat is subject to
sequential monomethylation and acetylation in cells, we performed mass spectrometry on immunoprecipitated Tat proteins
and generated new modification-specific Tat antibodies against monomethylated/acetylated Tat. No bimodified Tat protein
was detected in cells pointing to a demethylation step during the Tat transactivation cycle. We identify lysine-specific
demethylase 1 (LSD1/KDM1) as a Tat K51-specific demethylase, which is required for the activation of HIV transcription in
latently infected T cells. LSD1/KDM1 and its cofactor CoREST associates with the HIV promoter in vivo and activate Tat
transcriptional activity in a K51-dependent manner. In addition, small hairpin RNAs directed against LSD1/KDM1 or
inhibition of its activity with the monoamine oxidase inhibitor phenelzine suppresses the activation of HIV transcription in
latently infected T cells. Our data support the model that a LSD1/KDM1/CoREST complex, normally known as a
transcriptional suppressor, acts as a novel activator of HIV transcription through demethylation of K51 in Tat. Small molecule
inhibitors of LSD1/KDM1 show therapeutic promise by enforcing HIV latency in infected T cells.
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Introduction
Epigenetic processes are critical in the regulation of gene expression
from the integrated HIV provirus and have become a focal point of
research in therapeutics for HIV latency. Latently infected T cells
persist in HIV-infected individuals despite highly active antiretroviral
therapy (HAART) and rekindle the infection when HAART is
discontinued [1,2]. In the majority of latently infected cells, HIV
infection is blocked at the transcriptional level. Therapeutic efforts are
aimed at permanently silencing HIV gene expression in latently
infected cells or at ‘‘flushing out’’ the viral reservoirs by reverting the
transcriptional silencing that lies at the core of HIV proviral latency.
Known epigenetic processes involved in the regulation of HIV
gene expression include DNA methylation [3,4], chromatin
remodeling events [5,6,7], posttranslational modifications of
histones [8,9] and posttranslational modifications of the HIV
Tat protein [10,11,12,13,14,15,16]. Tat is an essential viral gene
product that potently activates HIV gene expression through its
unique interactions with the TAR element located at the 59 ends of
nascent viral transcripts and the cellular positive transcription
elongation factor b (P-TEFb) [17,18]. Two Tat species naturally
exist in HIV-infected cells: a full-length Tat protein of ,101 aa
length encoded by both tat exons and a shorter splice variant of 72
aa length encoded by the first tat exon. Both Tat forms are
transcriptionally active and form a trimolecular complex with the
cyclin T1 subunit of P-TEFb and TAR RNA to recruit the kinase
activity of CDK9 to elongating HIV transcripts. The bulk of Tat is
produced after successful integration of the provirus into the host
genome where it activates its own production via a feed-forward
mechanism [19].
Several posttranslational modifications of Tat have been
identified that modulate the interactions of Tat with P-TEFb
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acetylation of K50 and monomethylation of K51, occur at
adjacent residues within the arginine-rich motif (ARM) in Tat, a
region involved in TAR RNA binding, nuclear localization and
protein stability [21]. K50 is the preferred target for the
acetyltransferase activity of p300/KAT3B in Tat while K51 is
monomethylated by the lysine methyltransferase Set7/9/KMT7
[10,11,16,22]. K50 and K51 are also targets of the acetyltrans-
ferase activity of hGCN5/KAT2A and the di- or trimethyltrans-
ferase activity of SETDB1/KMT1 [15,22].
K50 acetylation and K51 monomethylation have both impor-
tant positive regulatory functions in Tat transactivation. Mono-
methylation of K51 strengthens the interactions of Tat with P-
TEFb and TAR RNA while acetylation of K50 dissociates the
Tat/TAR/P-TEFb complex and recruits the PCAF/KAT2B
histone acetyltransferase to the elongating RNA polymerase II
complex [16,23,24,25]. These findings form the basis for a
dynamic view of the Tat transactivation cycle in which changes in
the modification status of Tat occur sequentially and govern
differential cofactor interactions of a single Tat molecule during
HIV transcription [26,27].
We were intrigued by the close proximity of the two
modifications in Tat (K50 acetylation and K51 methylation) and
speculated that a bimodified protein may exist in cells. Similar
studies were previously performed with the p53 tumor suppressor
protein and supported the model that lysines in close proximity to
each other are sequentially methylated and acetylated [28,29].
However, we did not detect bimodified Tat in cells using mass
spectrometry or newly generated antibodies specific for mono-
methylated/acetylated Tat. Instead, we identified LSD1/KDM1
as a Tat demethylase and an unexpected new transcriptional
coactivator required for activation of HIV gene expression in
latently infected T cells.
Results
Acetylation of K50 inhibits monomethylation of K51 in
Tat in vitro
To examine how acetylation of K50 affects monomethylation of
the neighboring K51 residue, we incubated short synthetic Tat
peptides (aa 48–58) carrying an acetylated lysine at position 50
with recombinant Set7/9/KMT7 enzyme and radiolabeled S-
adenosyl-L-methionine (SAM). Reactions were dissolved on a high
percentage Tris-Tricine gel and examined by autoradiography.
Acetylation at K50 completely suppressed methylation of the
peptide by Set7/9/KMT7 (Figure 1A). The same was observed
when a K51-monomethylated peptide was tested in the reaction
indicating that K50 is not a target of the Set7/9/KMT7
monomethyltransferase activity (Figure 1A). We also performed
the inverse experiment and incubated a Tat peptide carrying a
monomethyl group at position 51 with the K50 acetyltransferase
p300/KAT3B and observed that acetylation can proceed, albeit
with a 40% decrease in efficiency as compared to an unmodified
peptide (Figure 1B). Interestingly, a K50-acetylated peptide was
further acetylated by p300/KAT3B confirming previous results
that K51 also functions as a target of the p300/KAT3B
acetyltransferase activity, especially when K50 is not available
[10,11,30]. Similar results were observed when the reactions were
performed with full-length synthetic Tat proteins (aa 1–72)
carrying acetylated K50 or monomethylated K51 residues (Figure
S1). These data demonstrate that in vitro monomethylation cannot
occur efficiently on an acetylated Tat substrate supporting
previous data that point to a role of K51 monomethylation early
in the Tat transactivation cycle before acetylation of K50 [16].
Because we find that K50 acetylation can occur in vitro when Tat is
monomethylated, we examined whether Tat is subject to
sequential monomethylation/acetylation in vivo.
Mass spectrometry of immunoprecipitated Tat
To search for monomethylated/acetylated Tat in cells, we
performed mass spectrometry of Tat immunoprecipitated from
TNFa-activated J-Lat A2 cells. This Jurkat-derived cell line harbors
an integrated bicistronic lentiviral vector, which expresses FLAG-
tagged Tatand GFP from the integrated HIV LTR (LTR-Tat-IRES-
GFP) upon stimulation with TNFa [31]. Immunoprecipitated
material was separated by SDS-PAGE and stained with FLAMIN-
GOfluorescence dye. The Tat band was cut from the gel and applied
to in-gel digestion with chymotrypsin. Residual digested peptides
were analyzed by MALDI-TOF/TOF mass spectrometry. A
representative MALDI-TOF MS spectrum of the digested peptides
i ss h o w ni nF i g u r e2 A ,a n dm o r et h a n1 0 0p e p t i d ei o ns i g n a l sw e r e
detected. A peptide encompassing the Tat ARM region without
modification was detected at 1084.681 m/z, which was identified as
t h ep e p t i d ef r o mg l y c i n e4 8t oa r g i n i n e5 5i nt h eT a t - F L A Gm o l e c u l e
by MALDI-TOF/TOF MS/MS analysis (Figure 2B). We also
detected a mass signal at 1197.724 m/z, which corresponded to the
Tat peptide from lysine 50 to arginine 57 carrying a monomethyl
group at lysine 51 (Figure 2C). Bimodified Tat (AcK50/Me1K51)
was not detected in this experiment. In addition, we did not detect
dimethylation at K51, but detected a peptide in which both K50 and
K51 carried a mass addition of 42 Da, indicating that these residues
could be either acetylated or trimethylated in cells (data not shown).
Mass spectrometry cannot differentiate efficiently between these two
modifications.We previouslyconfirmed that acetylation of K50 exists
in cells using acetylation-specific Tat antibodies [25] but could not
detect trimethylation of K51 using trimethyl-Tat-specific antibodies
[32] supporting a model where both residues may be acetylated
rather than trimethylated in cells. Further experiments using
modification-specific antibodies directed against both sites are
currently underway.
Bimodified Tat is not detected in cells
To independently analyze the existence of bimodified (AcK50/
Me1K51) Tat in cells, we generated a polyclonal antiserum
specific for doubly modified Tat. ARM peptides carrying an acetyl
Author Summary
One of the remaining questions in HIV research is how the
virus establishes a dormant (latent) stage and thereby
escapes eradication by current antiretroviral therapy.
Latently infected T cells do not produce significant
amounts of viral genomes or viral proteins due to the
silencing of a specific step in the viral life cycle called
transcription. Viral transcription can be reactivated in
latently infected cells, a process that rekindles HIV
infection after antiretroviral therapy is discontinued. A
key regulator of viral transcription is the viral Tat protein.
Here we identify a novel cellular enzyme that regulates HIV
transcription through the modification of the Tat protein.
This enzyme, LSD1, is generally known as a transcriptional
suppressor. In HIV infection, however, it acts as a
transcriptional activator because downregulation of LSD1
expression or inhibition of its enzymatic activity suppress-
es reactivation of HIV from latency. Our findings provide
novel insight into the mechanisms of HIV latency and
identify a potential new strategy that may help to keep HIV
dormant in latently infected cells.
LSD1 Activates HIV Transcription
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injected into rabbits and affinity purified on a column carrying the
bimodified antigen. The resulting antibodies (a-AcK50/Me1K51
Tat) were specific for the bimodified ARM peptides and did not
react with singly modified peptides in dot blot analysis (Figure 3A).
In contrast, an antiserum that we previously generated against
monomethylated K51 in Tat (a-Me1K51 Tat) [16] reacted with
ARM peptides monomethylated at K51 as expected but also
showed cross-reactivity with bimodified peptides (Figure 3A). The
same results were obtained when we tested the antibodies by
western blot analysis of synthetic Tat proteins (aa 1–72), which
carried either one or both modifications. The a-AcK50/Me1K51
Tat antibodies specifically recognized doubly modified Tat while
the a-Me1K51 Tat recognized both methylated and doubly
modified Tat (Figure 3B). No cross-reactivity was observed with
unmodified or acetylated Tat.
Totest whetherdoublymodified Tatexistsincells,wetransfected
FLAG-tagged Tat into 293T cells and purified Tat with a-FLAG
agarose. K51 methylated Tat was readily detected by western blot
analysis using a-Me1K51 Tat antibodies while no signal was
detected with the a-AcK50/Me1K51 Tat antibodies (Figure 3C).
Of note, both antibodies recognized their cognate antigens with
similar sensitivities as shown by western blot analysis of full-length
synthetic methylated and acetylated/methylated Tat proteins
(Figure 3C). Similar experiments were performed with antibodies
against AcK50Me2K51 and AcK50Me3K51 in Tat and showed no
reactivity with Tat in cells (data not shown). This result confirms the
data obtained by mass spectrometry, which indicate that doubly
modified Tat is not a major Tat species in cells.
LSD1/KDM1 demethylates Tat at K51
We speculated that Tat is demethylated at K51 before
acetylation occurs. Recombinant LSD1/KDM1 demethylated
synthetic monomethylated Tat in a dose-dependent manner as
shown by western blot analysis using a-Me1K51 Tat antibodies
(Figure 4A). LSD1/KDM1 also demethylated its cognate
substrate, dimethyl lysine 4 in histone H3, as expected
(Figure 4B). Interestingly, LSD1/KDM1 demethylated mono-
methylated Tat in vitro regardless of whether the neighboring K50
residue was acetylated or not, suggesting that LSD1/KDM1 may
demethylate Tat in cells either before or immediately after
acetylation had occurred (Figure 4C).
To test whether LSD1/KDM1 is involved in the demethylation
of Tat in cells, we introduced lentiviral vectors carrying shRNAs
against LSD1/KDM1 into J-Lat A2 cells and reduced endogenous
expression of LSD1/KDM1 (Figure 4D). We then induced
expression of Tat with TNFa and monitored monomethylation
of Tat K51 using western blotting with a-Me1K51 Tat antibodies.
Monomethylation of Tat was 2.6-fold enhanced in cells expressing
shRNAs against LSD1/KDM1 as compared to cells expressing
control shRNAs although the overall expression of Tat was
reduced (Figure 4D). This reduction is explained by the negative
effect of LSD1-knockdown on Tat transcriptional activity (see
below), which drives Tat expression from the LTR in these cells.
Collectively, these results demonstrate that LSD1/KDM1 de-
methylates Tat K51 in vitro and in cells.
LSD1/KDM1 associates with the HIV promoter in vivo
To test whether LSD1/KDM1 interacts with Tat in cells,
FLAG-tagged Tat proteins were expressed in 293T cells after
transient transfection. Following immunoprecipitation with a-
FLAG antibodies, endogenous LSD1/KDM1 was detected by
western blotting in the immunoprecipitated material (Figure 5A).
Tat proteins carrying point mutations either in K50 (K50A) or
K51 (K51A) also efficiently coimmunoprecipitated with LSD1/
KDM1 indicating that the interaction was not dependent on
Figure 1. In vitro acetylation and methylation assays using synthetic Tat peptides. (A) In vitro methylation assays of Tat ARM peptides (aa
45–58). Unmodified, K50-acetylated or K51-methylated peptides were incubated with recombinant SET7/9/KMT7 and
3H-radiolabeled S-adenosyl-L-
methionine (SAM). Peptides were separated by Tris-Tricine gel electrophoresis and visualized by autoradiography. A quantification of band intensities
of three independent experiments is shown below. (B) In vitro acetylation assays of Tat ARM peptides. Unmodified, K50-acetylated or K51-methylated
peptides were incubated with recombinant p300-HAT and
14C-acetyl coenzyme A. Peptides were processed as in A. A quantification of band
intensities of three independent experiments is shown below.
doi:10.1371/journal.ppat.1002184.g001
LSD1 Activates HIV Transcription
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was observed when we tested Tat’s interaction with the LSD1/
KDM1 cofactor CoREST [33,34] suggesting that Tat may recruit
a functional LSD1/KDM1/CoREST complex to the HIV
promoter. In contrast, no interaction of Tat or Tat mutants was
observed with cellular HDAC1, often also described as part of
LSD1/KDM1/CoREST corepressor complexes [35], [36], [33],
[37]. It is not clear at the moment whether the observed
interactions of Tat with LSD1/KDM1 or CoREST are direct or
mediated by other cellular proteins.
To test the hypothesis that LSD1/KDM1 and CoREST are
recruited to the HIV LTR, we performed chromatin immuno-
precipitation assays. Chromatin was prepared from J-Lat A2 cells,
in which Tat expression was stimulated by TNFa treatment or
which were left nonstimulated. Quantitative PCR analysis of the
immunoprecipitated material with primers specific for the HIV
LTR indicated that LSD1/KDM1 and CoREST, while only
present at low concentrations at the promoter under nonstimu-
lated conditions, were specifically recruited in response to TNFa
stimulation (Figure 5B, LSD1 and CoREST). No signal was
detected when immunoprecipitation was performed with beads
alone (Figure 5B, Control). Overall cellular expression of LSD1/
KDM1 and CoREST was unchanged in response to treatment
with TNFa in J-Lat A2 cells (Figure 5C). These results
demonstrate that LSD1/KDM1 and CoREST are recruited to
the HIV LTR in response to Tat. However, recruitment may also
occur indirectly via other LTR activators in response to TNFa
treatment.
Figure 2. MALDI-TOF mass spectrometric analysis of cellular Tat confirms K51 monomethylation. (A) MALDI-TOF MS spectrum of
digested peptides from Tat-FLAG (900-1,500 m/z) immunoprecipitated from J-Lat A2 cells activated with TNFa. The peptide ions (designated as A and
B) further analyzed by MS/MS are indicated by m/z values and number of amino acid sequence. Their position within the Tat-FLAG molecule used in
this study is indicated below. Please note that studies were performed with chymotrypsin to avoid restraints in trypsin-based cutting caused by
modifications of lysines. However, some identified ARM peptides are shorter than anticipated based on the predicted size of chymotrypsin-digested
peptides in Tat which is likely due to a contamination with some trypsin-like activity in the chymotrypsin preparations used in this experiment. (B)
MALDI-TOF/TOF MS/MS spectra of peptide A ion (1084.681 m/z). (C) MALDI-TOF/TOF MS/MS spectra of peptide B ion (1197.724 m/z). In these spectra,
identified fragment ions were denoted by the ion types, a, b, c, y according to the nomenclature by Roepstorff and Fohlman [57]. The assignment of
fragment ions to the amino acid sequence of the ARM region of the Tat molecule was inserted in each spectrum. The symbol * indicates methylated
amino acid residue.
doi:10.1371/journal.ppat.1002184.g002
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using a-Me1K51 or a-AcK50/Me1K51 Tat antibodies. (B) Western blot analysis of synthetic Tat (aa 1–72) with a-Tat, a-Me1K51 Tat or a-AcK50/Me1K51
Tat antibodies. Of note, we have not succeeded so far to synthesize a Tat peptide of 101 aa length corresponding to the full-length Tat species
encoded by two tat exons in cells. (C) Whole cell lysates from 293T cell transfected with FLAG-tagged Tat (aa 1–101) were subjected to
immunoprecipitation with a-FLAG agarose. Purified proteins were analyzed by western blot analysis together with synthetic Tat proteins using the
indicated antibodies.
doi:10.1371/journal.ppat.1002184.g003
Figure 4. LSD1/KDM1 demethylates mono-methylated K51 in Tat. (A) Synthetic K51-mono-methylated Tat proteins were incubated with
increasing amounts of recombinant LSD1/KDM1 (0, 0.5, 1, 2 mg) for 1 h at 37uC. Reaction products were analyzed by western blotting using a-Tat, a-
Me1K51 Tat antibodies. (B) Purified histone proteins were subjected to the same procedure as in A and analyzed by a-Me2H3K4 or a-histone H3
antibodies. (C) Synthetic K51-mono-methylated Tat or K50-acetylated/K51-monomethylated Tat proteins were incubated with 1 mg of recombinant
LSD1 as described in A. (D) Increase in K51-monomethylation of Tat in LSD1 shRNA-infected J-Lat A2 cells. Whole cell lysates isolated from J-Lat A2
cells infected with shRNAs directed against LSD1 or control shRNAs and stimulated with TNFa were analyzed by western blotting with indicated
antibodies. Band intensities were quantified using ImageJ Software (NIH). R.I.: Relative intensities of bands as compared to the control-vector
transduced cells (100%).
doi:10.1371/journal.ppat.1002184.g004
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To test the function of LSD1/KDM1 in HIV transcription, A2
cells were transduced with lentiviral vectors expressing two
different shRNAs directed against LSD1/KDM1 or control
shRNAs directed against firefly luciferase or a scrambled shRNA.
All vectors also expressed the mCherry marker to track infection
efficiencies. More than 90% of cells expressed mCherry after
lentiviral vector infection, and no difference in infection
efficiencies was observed between the different lentiviral vectors
(not shown). ShRNA-expressing cells were stimulated with TNFa,
and expression of GFP was measured by flow cytometry. GFP
expression was reduced by 40-60% in LSD1/KDM1 knockdown
cells as compared to cell lines expressing luciferase or scrambled
shRNAs (Figure 6A). No toxicity of LSD1 knockdown was
observed in shRNA-treated cells as measured by dye exclusion
in flow cytometry (Figure 6B). ShRNA#1 had a stronger
suppressive effect on GFP expression than shRNA#2 mirroring
the degree of LSD1/KDM1 knockdown in these cells (Figure 6C).
The same result was obtained in 5A8 J-Lat cells harboring a full-
length GFP-tagged latent HIV genome (Figure S2). Here,
reactivation from latency is achieved by stimulation with a-
CD3/CD28 antibodies in ,40% of cells. Only 5 or 15% of cells
reactivate HIV transcription in cells treated with LSD1#1o r
LSD1#2 shRNAs, respectively, confirming that LSD1 is impor-
tant for full transcriptional activity after reactivation from latency
after T cell receptor stimulation (Figure S2). A similar suppression
of GFP expression in the absence of cell toxicity was observed in
A2 cells, in which the expression of CoREST was downregulated
(Figure 6D–F). Interestingly, in A72 cells, in which GFP expression
is driven by the LTR alone in the absence of Tat, no effect of
either downregulation of cellular LSD1 or CoREST expression
was observed pointing to a specific effect of LSD1/KDM1 and
CoREST in Tat transactivation (Figure S3). Collectively, these
results demonstrate that an LSD1/KDM1/CoREST complex,
often a suppressor of cellular gene expression, functions as a co-
activator of HIV transcription.
To test whether LSD1/KDM1 activates HIV transcription
through Tat demethylation, we introduced siRNAs specific for
LSD1/KDM1 or control siRNAs into HeLa cells. Cells were then
co-transfected with the HIV LTR luciferase reporter gene and an
expression construct for Tat. Tat transactivation of the HIV LTR
was suppressed by ,50% when expression of LSD1/KDM1 was
reduced in cells indicating that LSD1/KDM1 is a positive cofactor
of Tat transactivation (Figure 6G). Expression of the TatK51A
mutant resulted in a similar decrease in Tat transactivation
(,50%) as previously reported [16], but no further reduction was
observed in LSD1/KDM1 knockdown cells supporting the model
that LSD1/KDM1 activates Tat transactivation through K51
demethylation (Figure 6G). The transcriptional activity of the HIV
LTR alone was also reduced in LSD1/KDM1 knockdown cells
(,28%) although values did not reach statistical significance
indicating that an additional target for LSD1/KDM1 may or may
not exist at the HIV LTR in the absence of Tat (Figure 6G).
Importantly, LSD1/KDM1 knockdown had no suppressive effect
on the EF-1a promoter that was driving Tat expression in these
co-transfection experiments excluding the possibility that LSD1/
KDM1 controls Tat expression and not Tat function (Figure 6G).
Successful knockdown of LSD1/KDM1 expression was confirmed
by western blotting (Figure 6H).
Phenelzine suppresses reactivation of HIV gene
expression from latency
Since LSD1/KDM1 belongs to the amine oxidase enzyme
superfamily that oxidatively removes methyl groups from di- or
monomethylated lysines, some monoamine oxidase (MAO)
inhibitors can act as LSD1/KDM1 inhibitors [34,38,39,40]. It
was recently reported that the MAO antidepressant agent
phenelzine (phenethylhydrazine) is far more potent in inhibiting
LSD1/KDM1 activity in cells than previously appreciated [38].
To test the activity of this agent in HIV infection, J-Lat A2 cells
were treated with increasing amounts of phenelzine or the CDK
inhibitor 5, 6-dichloro-1-b-D-ribofuranosyl-1H-benzimidazole
(DRB), a known Tat inhibitor. Phenelzine, similar to DRB,
prevented TNFa-mediated activation of gene expression in a dose-
dependent manner, albeit at ,150 fold higher concentrations than
DRB (IC50=300 mM Figure 7A, white circle). No cell toxicity was
observed for both agents at the tested concentrations (Figure 7A,
black circle).
The same experiment was performed in a primary T cell model
of HIV latency. Quiescent CD4+ T cells were isolated from blood
of two healthy donors and were spin-inoculated with an infectious
clone of HIV expressing luciferase within the nef open reading
frame following a similar protocol as previously described [41].
Infected CD4+ cells were cultured with the integrase inhibitor
saquinavir for 3 days to ensure that postintegration latency was
measured and then treated with increasing amounts of phenelzine
followed by stimulation with a-CD3 and a-CD28 antibodies to
activate latent HIV transcription. Activation of luciferase expres-
sion was successfully suppressed by phenelzine treatment confirm-
Figure 5. In vivo recruitment of LSD1 and CoREST to the HIV
LTR. (A) Co-immunoprecipitation of endogenous LSD1 and CoREST
with Tat/FLAG and the Tat K51A mutant in transiently transfected 293T
cells. (B) Chromatin immunoprecipitation analysis of LSD1, CoREST and
HDAC1 in J-Lat A2 cells. A2 cells were stimulated with TNFa over night
and chromatin immunoprecipitation was performed using a-LSD1, a-
CoREST, a-HDAC1 or no antibodies followed by real-time RT-PCR with
primers specific for the HIV LTR region. (C) Whole cell lysates isolated
from A2 cells stimulated with TNFa over night were analyzed by
western blotting using a-LSD1, a-tubulin or a-FLAG antibodies.
doi:10.1371/journal.ppat.1002184.g005
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infectious clone of HIV in primary T cells (Figure 7B). A slight
decrease in cell viability was observed in one donor at the highest
concentration of phenelzine (Figure 7B). However, no effect of
phenelzine on cell viability was observed in additional two donors,
in whom reactivation from HIV latency were also successfully
inhibited by the drug (Figure S4). Interestingly, in activated
primary T cells, phenelzine was more efficient in suppressing HIV
gene expression than DRB while in latently infected, but not
activated, cells phenelzine, contrary to DRB, had no suppressive
effect on luciferase expression (Figure S5). Collectively, these
results identify phenelzine as a potent new inhibitor of HIV
reactivation from latency and support the model that LSD1/
KDM1 is a novel activator of HIV transcription through Tat
demethylation.
Discussion
We investigated whether Tat lysine methylation and acetylation
events within the Tat ARM are linked via a demethylation step
mediated by LSD1/KDM1. Similar to previous reports on the
tumor suppressor p53 [28,29], we find that methylation and
acetylation of Tat can occur sequentially in vitro with methylation
at K51 occurring first allowing subsequent acetylation of K50,
albeit at diminished efficiency. Detailed in vivo analysis of the Tat
ARM reveals that a bimodified Tat form does likely not exist in
cells because it was not detected by mass spectrometry and by
western blotting using newly generated bispecific Tat antibodies.
Instead, we identify LSD1/KDM1 as a K51-specific Tat
demethylase and a novel transcriptional activator of HIV
transcription. These findings may be clinically relevant because
Figure 6. LSD1/KDM1 and CoREST activate HIV transcription. (A) Lentiviral vectors expressing shRNAs against LSD1 (#1 and #2), luciferase
or scrambled shRNAs were infected into J-Lat A2 cells for 5–10 days; cells were then stimulated with a low dose of TNFa (0.08 ng/ml) over night.
Number of GFP+ cells was analyzed by flow cytometry and expressed as percent GFP+ cells as compared to luciferase-shRNA-infected A2 cells. The
average (mean6SEM) of three independent experiments is shown. *corresponds to a p value ,0.01. (B) Number of violet dye-negative cells was
measured as a marker of cell viability by flow cytometry in cells described in (A). Of note, propidium iodide (PI) staining could not be performed in
these cells because of the mCherry marker expressed by the LSD1 shRNA vector (C) Whole cell lysates from shRNA-expressing cells were analyzed by
western blotting using a-LSD1 and a-tubulin antibodies. (D) Lentiviral vectors expressing shRNAs against CoREST (#1 and #2) or control shRNAs
were infected into J-Lat A2 cells. The same experiment as in (A) was performed. The average (mean6SEM) of three independent experiments is
shown. *corresponds to a p value ,0.01. (E) Number of PI-negative cells was measured as a marker of cell viability by flow cytometry in cells
described in (D). (F) Whole cell lysates from shRNA-infected A2 cells were analyzed by western blotting using a-CoREST and a-tubulin antibodies. (G)
SiRNA-transfected HeLa cells (48 h after siRNA transfection) were re-transfected with an HIV LTR luciferase reporter construct and expression vectors
for wildtype or K51A mutant Tat. In parallel, same amounts of EF-1a RL reporter constructs as used for Tat were transfected to monitor Tat expression.
Luciferase or Renilla activities were measured 24 h after plasmid transfections. The relative differences in luciferase activity as compared to wildtype
Tat transactivation were calculated. The average (mean6SEM) of three independent experiments is shown. *corresponds to a p value ,0.01. (H)
Whole cell lysates from siRNA-transfected HeLa cells were analyzed by western blotting using a-LSD1 and a-tubulin antibodies.
doi:10.1371/journal.ppat.1002184.g006
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against LSD1/KDM1, successfully suppresses re-activation of
HIV transcription in latently infected T cells.
Until recently, it was unclear whether methylation of lysines is
reversible. Today, there exist two types of lysine demethylases,
LSD1/KDM1 and Jumoji C domain-containing demethylases
[42]. LSD1/KDM1 is a flavin adenine dinucleotide (FAD)-
dependent amine oxidase, which can demethylate lysine 4 in
histone H3 (an activatory mark) and lysine 9 in histone H3 (a
silencing mark). LSD1/KDM1 can remove methyl groups from
mono- or di-, but not tri-methylated lysines [43,44]. Since the
FAD-dependent amine oxidase family of enzymes, which includes
MAO-A, MAO-B and LSD1/KDM1, share a common mecha-
nism for the oxidative cleavage of the unactivated nitrogen, known
MAO inhibitors such as phenelzine used in this study or others
have activity against LSD1/KDM1 [34,38,39,40].
It was recently reported that besides histones, LSD1/KDM1
can also demethylate non-histone proteins including the tumor
suppressor p53, the DNA methylase Dnmt1, and transcription
factor E2F1 [45,46,47,48]. Demethylation of p53 by LSD1 alters
the interaction of p53 with its coactivator 53BP1 and represses the
proapoptotic function of p53 [45]. Similarly, demethylation of
Dnmt1 by LSD1 triggers a loss of protein stability and a loss of
global DNA methylation while demethylation of E2F1 is required
for E2F1 stabilization and apoptotic function [46,47]. Our finding
that Tat function is activated by LSD1/KDM1-mediated
demethylation adds another nonhistone protein to the growing
list of LSD1/KDM1 substrates. Like E2F1, Tat is activated by
LSD1/KDM1 demethylation, a finding that supports the model
that the coordinated occurrence of Tat modifications is essential
for efficient Tat transcriptional activity.
Our finding that LSD1/KDM1 and CoREST are both
recruited to the activated HIV LTR in vivo points to Tat
demethylation as a novel mechanism how HIV may corrupt the
function of a known corepressor complex to enhance its own
replication. The interaction with CoREST is known to direct the
LSD1/KDM1 activity towards lysine 4 in nucleosomal histone H3
and is associated with transcriptional repression [33,34]. However,
LSD1/KDM1 can also act as a transcriptional activator for
instance through demethylation of lysine 9 in histone H3 in
conjunction with androgen receptor-mediated transcription [44],
through demethylation of lysine 9 in histone H3 in a-herpesvirus
infections [49] or through demethylation of the E2F1 transcription
factor which activates its apoptotic function [46]. Evidence that
support a role of Tat demethylation in the LSD1/KDM1
coactivator function in HIV transcription comes from the Tat
K51A mutant, which remains unaffected by siRNA-mediated
downregulation of LSD1/KDM1 expression. However, other
LSD1 substrates may exist at the HIV promoter that activate HIV
transcription when Tat is absent. An attractive target is methylated
lysine 9 in histone H3 at the HIV provirus, which was previously
linked to HIV latency [9,50,51] and is the target of the activatory
function of LSD1/KDM1 in the transcriptional control of herpes
simplex virus- and varicella zoster virus latency [49]. Notably, a
recent study shows that the latter function also involves CoREST
indicating that a functional LSD1/KDM1/CoREST complex can
function as suppressor of cellular gene expression or as activator of
viral transcription [52]. Interestingly, HDAC1/2 are generally
part of this complex, but we do not observe any interaction of Tat
with HDAC1 in our study. This may point to HDAC2 or another
HDAC associated with the LSD1/KDM1 subcomplex recruited
to the HIV LTR or may indicate that Tat specifically dissociates
HDACs from LSD1/KDM1 complexes involved in its demeth-
ylation. Notably, binding of CoREST, but not HDAC1, to LSD1/
KDM1 restored the ability of recombinant LSD1 to demethylate
nucleosomal substrates while HDACs are thought to act upstream
of LSD1/KDM1 by providing hypoacetylated substrates for
demethylation [33].
We focused here on the interaction between Tat demethylation
at K51 and K50 acetylation, but interplay may also exist between
K51 demethylation and other known Tat modifications such as
arginine methylation within the Tat ARM (Table S1). We have
previously shown that both acetylation and deacetylation of K50
in Tat are required for full Tat transactivation. While acetylation
of K50 by p300/KAT3B dissociates Tat from TAR RNA and P-
TEFb, deacetylation by SIRT1 may be necessary to recycle
Figure 7. LSD1/KDM1 as a potential drug target in HIV transcription. (A) J-Lat A2 cells were stimulated with 0.08 ng/ml of TNFa in the
presence of increasing amounts of phenelzine (100, 300, 1000 or 3000 mM), DRB (0.3, 1, 3 or 10 mM) or DMSO as carrier control overnight. Numbers of
GFP+ cells (marker of HIV LTR activity) as well as propidium iodide (PI)-negative cells (marker of cell viability) were analyzed by flow cytometry. The
percentage compared to DMSO-treated control cells was calculated. The average of two independent experiments is shown. (B) Purified resting
primary CD4+ T cells were infected at a high m.o.i. with infectious HIV-NL4-3 luciferase reporter virus. Three days after infection, cells were stimulated
with a-CD3 and a-CD28 antibodies in the presence of phenelzine (100, 300, or 1000 mM), DRB (1 or 10 mM) or DMSO overnight followed by analysis
for luciferase activity and PI uptake.
doi:10.1371/journal.ppat.1002184.g007
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Here, we show that the same ‘‘Yang/Yang’’ principle applies to
methylation and demethylation of K51 in Tat. Both, methylation
of K51 by Set7/9/KMT7 and demethylation of K51 by LSD1/
KDM1 activate Tat transactivation because knockdown or
inhibition of each enzyme leads to reduction of Tat transcriptional
activity in a K51-dependent manner. We propose a model where
demethylation of Tat occurs as a critical step during the Tat
transactivation cycle possibly before acetylation of Tat by p300/
KAT3B occurs (Figure 8). In support of this model, we have
previously shown that monomethylation of Tat is an early event
that strengthens the interaction of Tat with TAR RNA and P-
TEFb [16]. In addition, we show here that in vitro monomethyla-
tion at K51 decreases efficient acetylation of K50 by p300/
KAT3B supporting the model that prior demethylation is required
to allow full Tat acetylation at K50 and possibly at K51 in cells.
We also found in preliminary experiments that LSD1/KDM1
coimmunoprecipitates with p300/KAT3B in cellular extracts
pointing to a potential recruiting function of LSD1/KDM1 for
p300/KAT3B to Tat (N. Sakane and M.Ott, unpublished data).
Our data provide important first evidence that LSD1 inhibitors
may function as therapeutics to suppress reactivation of HIV
transcription in latently infected cells. They further support the
model that targeting Tat posttranslational modifications may be a
valid therapeutic strategy to control HIV transcription and
latency; Tat becomes ‘‘locked’’ in one modified state when
individual modifying enzymes are blocked and the normal flow of
Tat modifications is disturbed. Interestingly, MAO inhibitors with
inhibitory functions towards LSD1/KDM1 have suppressive
activity in latent infections of a-herpesvirus [49]. Our results
indicate that they may have a broader antiviral application that
includes HIV-1. The development of more specific LSD1/KDM1
inhibitors will bring further validation to the model that LSD1/
KDM1 is an important new drug target in the treatment of latent
HIV infection.
Methods
Cells, reagents and antibodies
HeLa and 293T cells (obtained from the American Type
Culture Collection), and the J-Lat clone A2 [31] were maintained
under standard cell-culture conditions. The following antibodies
were commercially available: a-LSD1/KDM1 (#ab51877, ab-
cam, Cambridge, MA), a-CoREST (#ab24166, abcam), a-FLAG
M2 (#F-3165 Sigma-Aldrich, St. Louis MO), a-histone
H3K4me2 (#07-030, Millipore, Billerica, MA), a-histone H3
(#07-690, Millipore), a-tubulin (#T6074, Sigma-Aldrich), a-Tat
(MMS-116P, Covance, Emeryville, CA), and a-CD28 (#16-0289-
85 eBioscience, San Diego CA). a-K51 monomethylated Tat
polyclonal antibodies were previously described [16]. a-CD3
(OKT-3) was obtained from the UCSF monoclonal antibodies
core facility. The a-HDAC1 polyclonal antibodies were a kind gift
of Eric Verdin, Gladstone Institute of Virology and Immunology,
San Francisco.
Phenelzine Sulfate was purchased from Spectrum Chemical
MHG Corp. (#3032 Gardena, CA) and Enzo Life Sciences (#EI-
217, Plymouth meeting, PA). Saquinavir was obtained from the
AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH. Recombinant human TNFa was purchased
from Humanzyme (#HZ-1014, Chicago, IL).
The synthetic Tat proteins (aa 1–72) was synthesized as
previously described [12] together with the Tat ARM short
peptide (aa 45-58) by Dr. Hans-Richard Rackwitz (Peptide
Specialty Laboratories GmbH, Heidelberg, Germany).
The HIV LTR luciferase construct, the EF-1a-Tat/FLAG
expression vector, the K51A mutated EF-1a-Tat/FLAG expres-
sion vector and the pEF-1a-RL (Renilla luciferase) were described
before [16]. The His-tagged LSD1 prokaryotic expression vector
was previously described (Department of Pathology, Harvard
Medical School, [43]).
A modified version of the pSicoR lentiviral vector that encodes the
mCherry reporter gene driven by an EF-1a promoter (pSicoRMS)
[53,54] was kindly provided by Matthew Spindler (Gladstone
Institute of Cardiovascular Disease). ShRNAs targeting LSD1
(LSD1 #1:GAAGGCTCTTCTAGCAATA, LSD1 #2: CATGT-
GCCTGTTTCTGCCATG) were cloned into pSicoRMS. The
pSicoRMScontaining anon-targeting controlsequence(shScramble:
GTCAAGTCTCACTTGCGTC) [55] and targeting luciferase
(shLuciferase: CTTACGCTGAGTACTTCGA) was kindly provid-
ed by Dr. Silke Wissing (Gladstone Institute of Virology and
Immunology). ShRNAs against CoREST and control empty
pLKO.1 vector were purchased from Thermo Fischer Scientific
(Waltham MA).
In-gel digestion and MALDI-TOF mass spectrometric
analysis of Tat protein
C-terminal FLAG-tagged Tat protein (Tat/FLAG) purified
from J-Lat A2 cells (,100 ng) was further purified by SDS-PAGE
(FLAMINGO gel stain, Bio-Rad Hercules, CA). Tat band was
excised and washed with 200 mL of 50 mM ammonium
bicarbonate containing 50% (v/v) ethanol followed by 200 mLo f
ethanol twice. The Tat protein in the gel was reduced with 10 mM
DTT in 50 mM ammonium bicarbonate for 1 h at 56uC and
alkylated with 55 mM iodoacetamide in 50 mM ammonium
bicarbonate for 30 min at room temperature. After reduction and
alkylation, the gel was dehydrated with acetonitrile 3 times. The
gel was rehydrated by adding 200 mL of 50 mM ammonium
Figure 8. Model of LSD1/KDM1 action in HIV transcription. Demethylation of Tat by the LSD1/KDM1/CoREST complex is a required new step
during Tat transactivation of the HIV LTR. We propose that it may occur before acetylation of Tat by p300/KAT3B. Inhibition of LSD1/KDM1 by
phenelzine blocks this demethylation step and inhibits Tat transactivation during reactivation from latency.
doi:10.1371/journal.ppat.1002184.g008
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Upper Bavaria, Germany) and incubated at 30uC for 2 h.
Digested Tat peptides were extracted from the gel with 1% (v/v)
formic acid containing 30% (v/v) acetonitrile followed by 1% (v/v)
formic acid containing 60% (v/v) acetonitrile. The extracted
peptide solution was dried up by speed vac. Then, residual
peptides were reconstituted with 30 mL of 0.1% (v/v) TFA
containing 2% (v/v) acetonitrile and desalted by ZipTipC18
(Millipore) according to the manufacturer’s description. 2 mLo f
cleaned peptide solution eluted from ZipTipC18 was deposited on
the Bruker metallic MALDI target (MTP384 ground steel, Bruker
Daltonics, Billerica, MA) and mixed with 2 mL of saturated matrix
solution (a-cyano-4-hydroxycinnamic acid solution in 33% (v/v)
acetonitrile, 0.1% (v/v) TFA). Peptide mixture was allowed to dry
at room temperature. The peptide mixture was analyzed by
ultraflex III TOF/TOF (Bruker Daltonics) MALDI-TOF/TOF
mass spectrometer, operated in reflector mode for positive ion
detection, and controlled by flexControl 3.0 software. For MS/MS
acquisitions, the ions of interest were fragmented by laser-induced
decay, and mass of fragments was analyzed using LIFT mode.
Monoisotopic mass was determined using flexAnalysis 3.0 software
with the SNAP peak picking algorithm. The modifications of
peptides were analyzed using UniMod database in the Biotools
software.
Generation of bimodified Tat antibodies
The strategy to generate bimodified Tat (AcK50/Me1K51)
specific antibodies was performed as previously described [16,32].
Briefly, KLH conjugated bimodified ARM peptides (AcK50/
Me1K51) were injected into rabbits. The same peptides were used
for affinity purification of the resulting antiserum. Specificity of
antibodies was monitored by dot-blot analysis using ARM peptides
and western blot analysis using synthetic full-length Tat proteins.
In vitro enzymatic assays
Protein expression and purification of recombinant LSD1 and in
vitro demethylation reactions of LSD1 (0.5–2.0 mg) with synthetic
Tat proteins (3 mg) or purified total cellular histones (8 mg) were
performed as previously described [43]. The reactions were
analyzed by western blotting using a-Me1K51 Tat antibodies
(1 mg ml). In vitro methylation reactions with synthetic Tat protein
(aa 1-72; 1 mg) and ARM peptides (aa 45-58; 100 mM), Set7/9-
KMT7 enzyme (2 mg Millipore), and
3H-S-Adenosyl Methionine
(Perkin Elmer) were performed as previously described [16]. In
vitro acetylation reactions with synthetic Tat proteins (1 mg), ARM
peptides (100 mM), GST-p300 HAT enzyme (aa 1195-1810; 5 mg;
[56]) and
14C-acetyl CoA (0.1 mCi; Perkin Elmer) were performed
as described [10]. Reactions were separated by SDS-PAGE or
Tris-Tricine gel electrophoresis and visualized by autoradiogra-
phy.
RNAi experiments
siRNA analysis for HeLa cells were performed as described
[16]. Briefly, HeLa cells were transfected with pooled LSD1 and
control siRNAs (200 pmol, Dharmacon; Lafayette, CO) using
Oligofectamine (#58303, Invitrogen, Carlsbad, CA) and were
retransfected after 48 h with the HIV LTR luciferase construct
(200 ng), Tat-expressing vectors (2 ng), and corresponding
amounts of the empty vector using lipofectamine reagent
(#50470, Invitrogen). Cells were harvested 24 h later and
processed for luciferase assays (Luciferase Assay System,
#E1501, Promega, Madison, WI) or western blotting.
J-Lat A2 cells were transduced with pseudotyped pSicoRMS-
derived lentiviral vectors expressing shRNAs against LSD1
(shLSD1 #1 and #2), against luciferase (shLuciferase) or a
nontargeting shRNA control (ShScramble). These lentiviral
vectors also express the mCherry protein under the control of
the EF-1a promoter (see cells, reagents and antibodies). 5 to 10
days after infection, cells were treated with 0.08 ng/ml of TNFa
for 12 h. Expression of GFP and mCherry was analyzed by flow
cytometry (BD LSRII, Beckton Dickinson, Franklin Lakes, NJ).
Similar experiments were performed using pLKO.1-derived
vectors expressing shRNAs against CoREST (shCoREST #1
and #2) or empty vector controls (shControl). When pLKO.1
vectors were used, puromycin was added one day after shRNA
infection (1 ng/ml). Cell viability was determined by propidium
iodide staining (#P-3566, Invitrogen) or LIVE/DEAD Fixable
Violet Dead Cell Stain Kit (#L34958, Invitrogen) followed by
flow cytometry.
Chromatin immunoprecipitation experiments
Chromatin immunoprecipitations from J-Lat A2 cells were
performed as previously described [4,16]. Chromatin solutions
were isolated from A2 cells treated with TNFa (2 ng/ml) and were
immunoprecipitated with a-LSD1 antibodies (abcam), a-CoREST
antibodies (abcam) or control rabbit pre-immune serum. The
immunoprecipitated material was quantified by real-time PCR
with primers specific for the HIV LTR using the ABI7700
Sequence Detection System (Applied Biosystems, Foster City, CA)
and the 2x Hot Sybr real-time PCR kit (#HSM-400, McLab,
South San Francisco, CA). Primer sequences were: HIV LTR
upstream: GAGCCCTCAGATCCTGCATA, HIV LTR down-
stream: AGCTCCTCTGGTTTCCCTTT.
Co-immunoprecipitation experiments
293T cells were transfected with Tat expressing vector using
Fugene 6 reagent (Roche). 24 h after transfection, cells were lysed
in IP buffer (250 mM NaCl, 0.1% NP40, 20 mM NaH2PO4
(pH 7.5), 5 mM EDTA, 30 mM sodium pyrophosphate, 10 mM
NaF and protease inhibitors) and immunoprecipitated with a-
FLAG M2 agarose (Sigma-Aldrich) over night at 4uC. Beads were
extensively washed and analyzed by western blotting with a-
LSD1, a-CoREST, a-HDAC1 or monoclonal a-FLAG antibod-
ies.
Primary T cell model of HIV latency [41]
The infectious NL4-3-luciferase clone of HIV was generated by
cloning the BamHI to XhoI fragment of pNL-Luc-E
-R
- within the
nef coding region into pNL4-3 [48]. This generates a fully
infectious clone capable of multiple rounds of infection and
producing luciferase driven from the LTR promoter. Infectious
particles were produced after transfection of the clone into 293T
cells. Two days after transfection, the transfected supernatants
were collected and concentrated by ultra-centrifuge (20,000 rpm,
2 h), and virus concentration was determined by analyzing
concentration of p24
gag (HIV-1 antigen p24 ELISA kit
#NEK050A001KT, Perkin Elmer). CD4+ T cells were isolated
from human whole blood buffy coats obtained from anonymous
donors by centrifugation onto a Histopaque-1077 cushion
(#10771, Sigma-Aldrich), enrichment of T cells by rosetting with
sheep red blood cells (#CS115 Colorado Serum, Denver, CO)
and depletion of non-CD4+ T cells with the CD4+ T cell isolation
kit (#130-091-155, Miltenyi Biotec Bergisch Gladbach, Germany)
and AutoMACS cell separator (Miltenyi Biotec). Purity of isolated
CD4+T cells was confirmed by flow cytometry. For infection, 1 mg
of p24
gag was used for 5610
6 CD4 T cells. The mixture of virus
and cells were centrifuged at 2400 rpm for 2 h. After spinocula-
tion, cells were cultured in the presence of 5 mM saquinavir for 3
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and a-CD28 antibodies (1 mg/ml, soluble) in the presence or
absence of phenelzine (100 mM–1 mM). After over night incuba-
tion, cells were harvested and processed for luciferase assays
(Luciferase Assay System, Promega). Cell viability was determined
by propidium iodide staining (#P-3566, Invitrogen).
Supporting Information
Figure S1 Interplay between Tat monomethylation at
K51 and acetylation at K50 using synthetic Tat proteins
(aa 1–72). (A) Radioactive in vitro methylation assays of synthetic
Tat and K50-acetylated synthetic Tat incubated with recombinant
SET7/9/KMT7 and
3H-radiolabeled S-adenosyl-L-methionine
(SAM). Reaction products were separated by SDS-PAGE and
visualized by autoradiography. (B) Radioactive in vitro acetylation
assays of synthetic Tat and K51-methylated synthetic Tat
incubated with recombinant p300-HAT and
14C-acetyl coenzyme
A. Reaction products were separated by SDS-PAGE and
visualized by autoradiography.
(TIF)
Figure S2 Reactivation of HIV expression from latency
is suppressed in full-length 5A8 J-Lat cells activated with
a-CD3/CD28 antibodies. For the generation of J-Lat cells
responsive to T cell activation, we employed a VSV-G
pseudotyped HIV reporter virus containing the GFP open reading
frame in place of the Nef gene (HIV-R7/Env-/GFP) as previously
described (Jordan et al., 2003, EMBO J, 22:1868-77) to infect
Jurkat cells at a multiplicity of infection of 0.1 for 96 h. GFP-
positive cells were sorted twice with a FACSDiva cell sorter
(Becton Dickinson) and discarded. GFP-negative cells were
propagated for 1 week and stimulated with plate-bound a-CD3
(10 mg/ml) and soluble a-CD28 (2 mg/ml) antibodies for 12 h.
GFP-positive cells were collected and propagated without
stimulation to allow silencing of LTR transcription. Single cells
were seeded in 96-well plates to generate cell clones. Examination
of six clones revealed that they all had the same integration site as
shown by repetitive Alu-gag PCR (Liszewski et al., 2009, Methods,
47:254-60). One of these clones, 5A8, was used in these
experiments. (A) Western blot analysis of LSD1 expression in
5A8 cells infected with indicated shRNAs. (B) 5A8 cells expressing
indicated shRNAs were re-stimulated with a-CD3/CD28 anti-
bodies overnight, and GFP was measured by flow cytometry. One
representative experiment performed in duplicate is shown.
(TIF)
Figure S3 LSD1/KDM1 and CoREST do not activate
basal transcription at the HIV-LTR. (A) Lentiviral vectors
expressing shRNAs against LSD1 (#1), luciferase or scrambled
shRNAs were infected into J-Lat A72 cells for 6 days; cells were
then stimulated with TNFa (10 ng/ml) over night. The number of
GFP+ cells was analyzed by flow cytometry and expressed as
percent GFP+ cells as compared to luciferase-shRNA-infected A72
cells. Results (mean6SD) of two independent experiments
performed in duplicate are shown. (B) Cell viability of infected
cells was assessed by LIVE/DEAD Fixable Violet Dead Cell Stain
Kit (Invitrogen). Violet dye-negative (thereby viable) cells were
analyzed by flow cytometry analysis. (C) Whole cell lysates from
shRNA-expressing cells were analyzed by western blotting using a-
LSD1 and a-tubulin antibodies. (D) Lentiviral vectors expressing
shRNAs against CoREST (#2) or control shRNAs were infected
into J-Lat A72 cells. The same experiment as in (A) was
performed. Results (mean6SD) of two independent experiments
performed in duplicate are shown. (E) Propidium iodide (PI)-
negative cells (marker of cell viability) were analyzed by flow
cytometry. (F) Whole cell lysates from shRNA-infected A72 cells
were analyzed by western blotting using a-CoREST and a-tubulin
antibodies.
(TIF)
Figure S4 Phenelzine treatment suppresses reactivation
of HIV transcription from latency in additional donors.
(A) Purified resting primary CD4+ T cells were infected at a high
m.o.i. with infectious HIV-NL4-3 luciferase reporter virus. Three
days after infection, cells were stimulated with a-CD3 and a-CD28
antibodies in the presence of phenelzine (100, 300, or 1000 mM) or
DMSO overnight followed by analysis of luciferase activity (B)
Propidium iodide (PI)-negative cells of CD4+ T cells from each
donor were analyzed by flow cytometry.
(TIF)
Figure S5 No effect of phenelzine on HIV transcription
in unstimulated resting primary CD4+ T cells. (A) Purified
resting primary CD4+ T cells were infected at a high m.o.i. with
infectious HIV-NL4-3 luciferase reporter virus and three days
after infection were treated with phenelzine (100, 300, or
1000 mM), DRB or DMSO overnight followed by analysis of
luciferase activity. (B) Propidium iodide (PI)-negative cells were
analyzed by flow cytometry. Results (mean6SEM) of one
experiment performed in triplicate are shown.
(TIF)
Table S1 Posttranslational modifications of conserved
residues in HIV-1 Tat and their effects on HIV
transcription.
(DOC)
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